Business
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
Invited Speaker at 2025 GenScript Biotech Global Forum MIRAMAR, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”),
About this update from Hcw Biologics Inc.
[{"type":"text","content":"Invited Speaker at 2025 GenScript Biotech Global Forum\nMIRAMAR, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic inflammation and disease, announced today that Hing C. Wong, PhD., Founder and CEO, will serve as a panelist on Panel Discussion II of the 2025 GenScript Biotech Global Forum as a thought leader regarding Conquering Cell and Gene Therapy (“CGT”) Challenges in Biomanufacturing and Supply Chain Management. The event is taking place on January 15, 2025, alongside the 2025 J.P. Morgan Healthcare Conference in San Francisco. Details are as follows: Event:2025 GenScript Biotech Global ForumPanelist:Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics Inc.Panel Discussion II:Conquering CGT’s Challenges in Biomanufacturing and Supply Chain ManagementTime: 4:05 PM - 5:00 PM PT, January 15, 2025Location:San Francisco Marriott Marquis, CA (In-person/Livestream)Event website:https://genscript-global-biotech-forum.cventevents.com/event/0027fbb0-b171-4f52-bcd9-ba57c357928e/home HCWB has developed immunotherapeutics administered by subcutaneous injection with its new drug discovery platform technology which the Company categorizes into three classes (https://hcwbiologics.com/technology/). In each of these classes, the Company has created molecules for potential treatment of hematologic and solid tumors, virally infected cells, and cellular senescence diseases associated with aging. Class I is Multi-Functional Immune Cell Stimulators; Class II is Second-Generation Immune Checkpoint Inhibitors and Multi-Specific Targeting Fusions; and Class III is Enhanced Immune-Cell Engagers. One of the greatest challenges for CGT is the cost of manufacturing, which can make them inaccessible to many patients. During the panel discussion, Dr. Wong will describe how utilizing CGTs in combination with some of the proprietary molecules the Company has constructed with its new drug discovery platform could potentially benefit CGT by significantly reducing costs and improving the clinical efficacy of engineered effector cells for CGT. In addition, Dr. Wong will discuss why he believes that Immune-Cell Engagers, which include ...